The bell's about to sound for the next round in a patent fight that the entire pharmaceutical industry is watching. Next week the biotechnology firm Ariad Pharmaceuticals (down $0.06 to $3.99, Charts) and the big drugmaker Eli Lilly & Co. (down $0.37 to $56.27, Charts) head back to court in a fight over a patent that Ariad claims gives it rights to a drug pathway. The pathway is the specific way a drug works in the human body. This is a highly unusual case since patents tend to cover a drug's composition, not the way it affects the body. (See correction.) .